R. Marschke

发表

Systemic adjuvant therapy in women with resected node-negative breast cancer.

D. Schaid, J. Ingle, L. Hartmann, 1991, Mayo Clinic proceedings.

Stratifying risks for patients with localized rectal cancer: Do all stage II patients require adjuvant radiation or chemoradiation?

J. Efron, T. Young‐Fadok, L. Gunderson, 2006 .

Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancer.

W. Maples, A. Schutt, J. Martenson, 1994, International journal of radiation oncology, biology, physics.

Etiologic considerations in superior vena cava syndrome.

J. Parish, R. E. Lee, D. E. Dines, 1981, Mayo Clinic proceedings.

Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma

S. Cha, R. Goldberg, J. Myers, 1996, Cancer.

Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.

M. Borad, D. V. Von Hoff, D. Northfelt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

J. Jett, H. Tazelaar, John Q. Su, 1992, Cancer.

Phase II trial of topotecan for the treatment of mesothelioma.

J. Jett, R. Marks, S. Nair, 1998, American journal of clinical oncology.

Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer

D. Schaid, J. Ingle, J. Krook, 1989, Cancer.

A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer.

J. Jett, J. Sloan, J. Knost, 2000, Lung cancer.

Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer

D. Schaid, J. Ingle, J. Krook, 1989, American journal of clinical oncology.

Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure

J. Ingle, L. Kvols, J. Laurie, 1985, American journal of clinical oncology.

MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

R. Lloyd, M. Mahoney, R. Donehower, 2007 .

Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer.

J. Ingle, J. Krook, V. Suman, 1997, American journal of clinical oncology.

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.

J. Krook, J. Kugler, S. Nair, 1998, American journal of clinical oncology.

Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma.

R. Marks, W. Maples, V. Suman, 1997, American journal of clinical oncology.

Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.

J. Ingle, J. Laurie, S. Green, 1985, Cancer treatment reports.

Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer.

J. Jett, J. Sloan, R. Morton, 1999, American journal of clinical oncology.

NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results

N. Foster, J. Kugler, S. Alberts, 2007 .

A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.

T. Fleming, J. Laurie, C. Moertel, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status.

J. Efron, T. Young‐Fadok, L. Gunderson, 2008, Gastrointestinal cancer research : GCR.

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

T. Fleming, J. Krook, J. Rubin, 1985, JAMA.

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma

E. Shaw, J. Sloan, E. Creagan, 1998, Cancer.

Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.

T. Therneau, J. Jett, J. Krook, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.

D. Schaid, J. Ingle, J. Mailliard, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer.

J. Ingle, D. Ahmann, S. Green, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

F. Sarkar, S. Sheng, E. Heath, 2005, Clinical prostate cancer.

A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

J. Grem, D. Northfelt, D. V. Hoff, 2007 .

Advanced colorectal adenocarcinoma: treatment with amonafide.

J. Kovach, M. O’connell, J. Rubin, 1994, Journal of the National Cancer Institute.

Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial.

T. Witzig, J. Gerstner, J. Mailliard, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial

D. Northfelt, D. V. Hoff, K. Anderes, 2010 .

A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.

T. Fleming, J. Jett, J. Laurie, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.